IUD Insertion After D&E Procedure (ILIAD)

This study has been completed.
Sponsor:
Information provided by:
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00475228
First received: May 16, 2007
Last updated: February 25, 2011
Last verified: February 2011
  Purpose

This study is a randomized controlled trial of insertion of the levonorgestrel-releasing intrauterine device (LNG-IUD) immediately following dilation & evacuation (D&E) compared to delayed insertion 3-6 weeks post-abortion. Eighty-eight women undergoing D&E between 15 0/7 and 23 6/7 weeks gestation will be enrolled at Magee-Womens Hospital, Pittsburgh, PA. The primary outcome is LNG-IUD usage six months following enrollment. We hypothesize that more women receiving immediate insertion will be using the LNG-IUD 6 months after the D&E procedure than women receiving delayed insertion. Secondary outcomes include the proportion receiving an IUD, continuation rate, complication rates, subject satisfaction, and quality of life. The utility of ultrasonography in predicting expulsion will also be examined. Anticipated problems include poor subject follow-up and coordinating the intra-operative study procedures.


Condition Intervention Phase
Contraceptive Usage
Drug: Levonorgestrel IUD
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Immediate Versus Delayed Insertion of the Levonorgestrel-Releasing Intrauterine Device Following Dilation and Evacuation: A Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • To assess the six-month usage rate of the LNG-IUD when placed immediately after D&E compared to 3-6 weeks later, as measured by the proportion of women with a LNG-IUD in place at six months after the D&E. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To examine what percentage of women receive the LNG-IUD in each group [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • To compare expulsion rates between immediate insertion and delayed insertion [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • To assess the continuation rates of the LNG-IUD [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • To examine the utility of ultrasonography in predicting expulsion [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • To assess subject's tolerance of the IUD placement and quality of life measures [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 93
Study Start Date: March 2007
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Insertion of IUD immediately after completion of D&E
Drug: Levonorgestrel IUD
intrauterine insertion for arm 1 immediately after D&E procedure and for arm 2 at 3-6 weeks post-procedurem
Other Name: Mirena
Active Comparator: 2
Insertion of IUD at standard time post-procedure (3-6 weeks post D&E procedure)
Drug: Levonorgestrel IUD
intrauterine insertion for arm 1 immediately after D&E procedure and for arm 2 at 3-6 weeks post-procedurem
Other Name: Mirena

Detailed Description:

The D&E will be performed by the investigator or a co-investigator in the usual fashion. The uterus will be sounded to the fundus. Once the D&E is complete, the surgeon will check the post-enrollment exclusion criteria to ensure that no events during the D&E made the subject ineligible. If the subject remains eligible, the randomization packet will be opened.

Immediately Post-D&E Procedure.

  1. Group 1: IUD will be placed per study protocol. The strings will be trimmed to be flush with the cervix. Using transabdominal sonography, the distance from the serosal surface of the uterine fundus to the distal tip of the IUD will be measured.
  2. Group 2: No additional procedures will be performed in the operating room.

Post-Operative Care. The subject will then be taken to the recovery room for routine post-operative care.

  1. Group 1: A brief questionnaire will be administered. No additional procedures will be performed in the recovery room.
  2. Group 2: A brief questionnaire will be administered. The subject will be asked to start her previously chosen method of contraception.
  3. Subjects will be given a digital thermometer and will be asked to call if any temperature exceeds 38°C (100.4°F). If a subject reports a fever (>38°C), an interim visit will be scheduled as described below.

Day 21-42. Post-Abortion Visit at 1 month (PAV 1): will be scheduled on a weekday between 8:30 am and 4:30 pm at the time most convenient for the subject. For Group 1, the visit may be on any day from day 21-42. For Group 2, the visit will be scheduled with the goal of inserting the LNG-IUD during the first 7 days of the menstrual cycle.

Subjects will complete a questionnaire about symptoms since the D&E, including pain and bleeding and subjects' history will be collected. Subjects also will complete a set of visual-analog scales about pain, bleeding, and quality of life. All subjects will have a bimanual exam to assess uterine size, cervical motion and adnexal tenderness. Women in Group 1 will have a speculum exam to measure and, if necessary, trim the IUD strings. The length of the segment trimmed will be measured and recorded. If cervicitis or vaginitis is suspected, further evaluation will be performed with diagnosis and treatment by CDC guidelines as indicated. Women in group 2 will have their IUD placed.

Day 56-70: Post-Abortion Visit at 2 months (PAV 2): may be scheduled any time within days 56-70 but must be at least 21 days after PAV1. Subjects will complete a questionnaire and visual-analog scales about symptoms since the D&E, including pain, bleeding, and quality of life and subjects' history will be obtained. Bimanual Examination will be performed to assess uterine size, cervical motion and adnexal tenderness. A speculum exam will be done to measure the strings and trim, if necessary. The IUD-Fundal Distance will be assessed by endovaginal sonography.

Day 160-200: Telephone Interview at 6 month (TI 6). A questionnaire will be administered over the phone. Three attempts will be made to contact the subject by telephone. A certified letter with the questionnaire and a postage-paid envelope will be sent if the subject is not contacted.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Gestational age from 15 weeks 0 days to 23 weeks 6 days at enrollment (time of D&E), confirmed by ultrasound
  2. Has already consented to an elective termination of pregnancy
  3. Desires to use the LNG-IUD (Mirena) for contraception for 12 months or more
  4. Willing and able to sign an informed consent
  5. Willing to comply with the study protocol
  6. Age greater than or equal to 18 years
  7. Primary residency in Allegheny, Beaver, Washington, Westmoreland, Butler, Armstrong, Indiana, Fayette, Greene, or Lawrence counties of Pennsylvania

Exclusion Criteria:

  1. Allergy to either polyethylene or levonorgestrel
  2. Urgent need for termination of pregnancy (active bleeding or infection)
  3. Exposure to or treatment for gonorrhea or Chlamydia within the past 90 days
  4. Diagnosis of pelvic inflammatory disease within the past year
  5. Presence of one or more leiomyomata greater than 3 centimeters in diameter
  6. Uterine anomaly (other than a repaired septate uterus)
  7. Current participation in any other intervention trial

Post-Enrollment Pre-Randomization Exclusion criteria (to be assessed at the completion of the D&E. These criteria will be used to define a group not eligible for immediate insertion. Since these complications contraindicate immediate insertion, the issue of whether immediate and delayed insertion is preferable is no longer in question.)

  1. Uterine perforation
  2. Hemorrhage as defined by one of the following: (1) need for transfusion; (2) estimated blood loss greater than 500 cc; (3) intrauterine placement of a Foley catheter; or (4) the use of 3 or more doses of uterotonic medications
  3. Evidence of infection at the time of the D&E, including fever (temperature ≥ 38°C) or pus at the cervical os
  4. Subject no longer desires a LNG-IUD
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00475228

Locations
United States, Pennsylvania
University of Pittsburgh Center for Family Planning Research
Pittsburgh, Pennsylvania, United States, 15215
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: Heather Hohmann, MD University of Pittsburgh
  More Information

No publications provided

Responsible Party: Heather Hohmann, MD, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00475228     History of Changes
Other Study ID Numbers: Pitt IRB PRO06040004
Study First Received: May 16, 2007
Last Updated: February 25, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
levonorgestrel IUD
IUD
dilation and evacuation
second trimester
contraception

Additional relevant MeSH terms:
Levonorgestrel
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Contraceptives, Oral, Synthetic
Contraceptives, Oral

ClinicalTrials.gov processed this record on April 15, 2014